Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cardiff Oncology Inc.

    NASDAQ: CRDF · Real-Time Price · USD
    3.88
    0.26 (7.18%)
    At close: Jun 06, 2025, 3:59 PM
    3.91
    0.77%
    After-hours: Jun 06, 2025, 07:32 PM EDT

    Cardiff Oncology Statistics

    Share Statistics

    Cardiff Oncology has 66.53M shares outstanding. The number of shares has increased by 48.74% in one year.

    Shares Outstanding

    n/a
    		 66.53M

    Shares Change (YoY)

    n/a
    		 48.74%

    Shares Change (QoQ)

    n/a
    		 0.01%

    Owned by Institutions (%)

    n/a
    		 59.94%

    Shares Floating

    n/a
    		 60.75M

    Failed to Deliver (FTD) Shares

    n/a
    		 2,176

    FTD / Avg. Volume

    n/a
    		 0.19%

    Short Selling Information

    The latest short interest is 17.52M, so 26.34% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 17.52M

    Short % of Shares Out

    n/a
    		 26.34%

    Short % of Float

    n/a
    		 27.04%

    Short Ratio (days to cover)

    n/a
    		 22.71

    Valuation Ratios

    The PE ratio is -4.55 and the forward PE ratio is -3.73. Cardiff Oncology's PEG ratio is -2.12.

    PE Ratio

    n/a
    		 -4.55

    Forward PE

    n/a
    		 -3.73

    PS Ratio

    n/a
    		 302.78

    Forward PS

    n/a
    		 2.8

    PB Ratio

    n/a
    		 2.49

    P/FCF Ratio

    n/a
    		 -5.47

    PEG Ratio

    n/a
    		 -2.12
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Cardiff Oncology.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.08, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 7.08

    Quick Ratio

    n/a
    		 7.08

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 -0.03

    Debt / FCF

    n/a
    		 -0.04

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $21,343.75

    Profits Per Employee

    n/a
    		 $-1,419,718.75

    Employee Count

    n/a
    		 32

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -24K

    Effective Tax Rate

    n/a
    		 0.05%

    Stock Price Statistics

    The stock price has increased by 32.42% in the last 52 weeks. The beta is 1.56, so Cardiff Oncology's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.56

    52-Week Price Change

    n/a
    		 32.42%

    50-Day Moving Average

    n/a
    		 2.94

    200-Day Moving Average

    n/a
    		 3.22

    Relative Strength Index (RSI)

    n/a
    		 75.64

    Average Volume (20 Days)

    n/a
    		 1,138,119

    Income Statement

    In the last 12 months, Cardiff Oncology had revenue of 683K and earned -45.43M in profits. Earnings per share was -0.95.

    Revenue

    n/a
    		 683K

    Gross Profit

    n/a
    		 279K

    Operating Income

    n/a
    		 -48.65M

    Net Income

    n/a
    		 -45.43M

    EBITDA

    n/a
    		 -48.25M

    EBIT

    n/a
    		 -48.65M

    Earnings Per Share (EPS)

    n/a
    		 -0.95
    Full Income Statement

    Balance Sheet

    The company has 51.47M in cash and 1.52M in debt, giving a net cash position of 49.95M.

    Cash & Cash Equivalents

    n/a
    		 51.47M

    Total Debt

    n/a
    		 1.52M

    Net Cash

    n/a
    		 49.95M

    Retained Earnings

    n/a
    		 -384.18M

    Total Assets

    n/a
    		 84.81M

    Working Capital

    n/a
    		 69.42M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -37.69M and capital expenditures -80K, giving a free cash flow of -37.77M.

    Operating Cash Flow

    n/a
    		 -37.69M

    Capital Expenditures

    n/a
    		 -80K

    Free Cash Flow

    n/a
    		 -37.77M

    FCF Per Share

    n/a
    		 -0.79
    Full Cash Flow Statement

    Margins

    Gross margin is 40.85%, with operating and profit margins of -7123.13% and -6651.68%.

    Gross Margin

    n/a
    		 40.85%

    Operating Margin

    n/a
    		 -7123.13%

    Pretax Margin

    n/a
    		 -6655.2%

    Profit Margin

    n/a
    		 -6651.68%

    EBITDA Margin

    n/a
    		 -7063.98%

    EBIT Margin

    n/a
    		 -7123.13%

    FCF Margin

    n/a
    		 -5530.45%

    Dividends & Yields

    CRDF does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CRDF is $10, which is 157.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $10

    Price Target Difference

    n/a
    		 157.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Feb 20, 2019. It was a backward split with a ratio of 1:6.

    Last Split Date

    n/a
    		 Feb 20, 2019

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:6

    Scores

    Altman Z-Score

    n/a
    		 1.54

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist